Paxlovid (nirmatrelvir And Ritonavir) - Dosing And Dispensing In Renal Impairment, Risk Of Serious Adverse Reactions Due To Drug Interactions, And English-only Labels
PAXLOVID Recall Summary Paxlovid (nirmatrelvir and ritonavir) tablets are being recalled across Canada due to labeling issues that don't adequately warn about dosing adjustments needed for people with kidney problems and serious drug interactions with other medications. The 150 mg nirmatrelvir/100 mg ritonavir product is affected nationwide.
- Product
- PAXLOVID (150 mg nirmatrelvir; 100 mg ritonavir)
- Reason
- Labelling - New safety information - Supply - COVID
- Category
- drug recall
- Country
- Canada
- Agency
- HC-DRUGS
- Recall date
- 2022-01-17
- Status
- Ongoing
- Distribution
- Canada-wide
Official recall notice from HC-DRUGS
Recall details on Nibble Recalls: https://trynibble.app/recalls/59269d08-6479-41a3-8b65-59eedaf3d90e